Journal of Diabetes Investigation: Vol. 10, Issue 5 Review
This issue of the Journal of Diabetes Investigation brings together vital research focusing on real-world treatment patterns, innovative diagnostic screening tools, gestational diabetes trends, and unexpected risk factors. Key themes highlight how clinicians select medications based on patient complications, how digital health interventions compare to traditional monitoring, and how everyday measurements—like serum creatinine and BMI—can predict complications in unique ways.
For patients and families, these studies underscore that diabetes care is increasingly personalized. From utilizing mobile apps for better blood sugar tracking to understanding how stomach infections or muscle-mass markers relate to diabetes, this research paves the way for more comprehensive and accessible care strategies.
This article was created with the assistance of AI. Although the content is based on original research articles and other academic sources, errors may be present. Please verify the information using the original articles and consult qualified healthcare professionals for medical advice.
Preferential Prescribing of Linagliptin in Type 2 Diabetes Patients with Comorbidities
Authors: Soulmaz Fazeli Farsani, Atsushi Taniguchi, Rie Ikeda, Kimberly G Brodovicz, Dorothee B Bartels
Research Objective: To evaluate how linagliptin (a DPP-4 inhibitor) is prescribed in real-world Japanese clinical practice compared to other glucose-lowering drugs in patients with various underlying health conditions.
Methods: An expanded post-marketing surveillance study in Japan enrolled over 4,200 patients starting either linagliptin monotherapy or another glucose-lowering medication between 2012 and 2014. Baseline demographic and medical data were compared between the groups.
Main Findings: Patients prescribed linagliptin had significantly higher rates of pre-existing health conditions compared to those starting other therapies. Notable differences were seen in metabolism/nutritional issues (50.5% vs 45.5%), cardiac disorders (12.2% vs 8.6%), vascular diseases (56.4% vs 51.3%), and renal/urinary tract complications (9.9% vs 5.7%).
Clinical Significance: This indicates a strong clinical preference for linagliptin in patients with complex medical backgrounds, likely because linagliptin does not require dose adjustments or intensive monitoring in patients with liver or kidney impairment.
Key Points for Patients: If you have kidney, heart, or blood vessel issues alongside type 2 diabetes, your doctor may choose specific medications like linagliptin because they are safer to use without adjusting doses as kidney function changes.
Real-World Safety and Efficacy of Tofogliflozin in Japanese Patients
Authors: Kazunori Utsunomiya, Masayuki Senda, Seigo Kakiuchi, Hiroyuki Kameda, Masahiro Tamura, Yuji Kurihara, Ryoji Gunji, Shoko Fujii, Hisataka Fujiwara, Kohei Kaku
Research Objective: To assess the safety, tolerability, and effectiveness of tofogliflozin (an SGLT2 inhibitor) in Japanese type 2 diabetes patients in daily clinical practice.
Methods: This was a 12-week interim analysis of a long-term, 3-year observational study enrolling 6,897 patients who started tofogliflozin because their blood sugar was inadequately controlled on current therapies.
Main Findings: Tofogliflozin significantly improved HbA1c levels (an average reduction of 0.63%) and reduced body weight (average reduction of 2.02 kg) across all body mass index (BMI) groups. Side effects were reported in 5.14% of patients and were mostly mild. Increased urination was more common in older adults (65 years and older), while urinary and genital tract infections occurred more frequently in women.
Clinical Significance: Tofogliflozin displays a highly favorable benefit-risk profile, supporting its short-term safety and effectiveness for weight and blood sugar control in real-world scenarios.
Key Points for Patients: Tofogliflozin is effective at lowering both blood sugar and body weight. However, patients—especially women and older adults—should stay hydrated and maintain good hygiene to prevent common side effects like increased urination or mild infections.
Low Serum Creatinine Levels Associated with Increased Diabetes Risk
Authors: Huanhuan Hu, Tohru Nakagawa, Toru Honda, Shuichiro Yamamoto, Hiroko Okazaki, Makoto Yamamoto, Toshiaki Miyamoto, Masafumi Eguchi, Takeshi Kochi, Makiko Shimizu, Taizo Murakami, Kentaro Tomita, Takayuki Ogasawara, Naoko Sasaki, Akihiko Uehara, Keisuke Kuwahara, Isamu Kabe, Tetsuya Mizoue, Tomofumi Sone, Seitaro Dohi
Research Objective: To investigate whether lower levels of creatinine in the blood—often an indicator of lower muscle mass—are linked to a higher risk of developing type 2 diabetes.
Methods: A long-term study tracked 31,343 Japanese male workers without diabetes (ages 20 to 64) for a median of 7.7 years, monitoring their blood creatinine levels and diabetes onset.
Main Findings: Lower average blood creatinine levels were strongly associated with a higher risk of developing diabetes. Men with the lowest levels (under 0.70 mg/dL) had a 56% higher risk of developing diabetes compared to those with standard levels (0.90 to 1.20 mg/dL). This association was even stronger in older adults.
Clinical Significance: Routine blood tests measuring creatinine (often checked to assess kidney health) might double as a helpful screening tool to identify individuals with low muscle mass who are at a higher risk of developing diabetes.
Key Points for Patients: Creatinine is a natural waste product of muscle. Low creatinine can suggest lower overall muscle mass. Keeping active and building muscle through regular exercise can help protect against diabetes.
Impact of Different Diagnostic Criteria on Gestational Diabetes Rates and Healthcare Spending in China
Authors: Zonglin He, Huatao Xie, Shangqiang Liang, Yuan Tang, Wenjing Ding, Yanxin Wu, Wai-kit Ming
Research Objective: To evaluate how different diagnostic guidelines for gestational diabetes mellitus (GDM) impact the number of women diagnosed and the overall healthcare costs in China.
Methods: Researchers analyzed maternal health records from 2011 to 2017 at a major university hospital, comparing how different national and international guidelines would classify the patients.
Main Findings: Implementing strict modern standards (such as the ADA 2011 guidelines) led to gestational diabetes rates of nearly 23%—over three times higher than older diagnostic textbook criteria. This increased diagnosis rate raised estimated nationwide GDM treatment costs from 3.9 billion RMB to 27.4 billion RMB. However, these stricter criteria were associated with fewer complications during birth and lower rates of long-term type 2 diabetes.
Clinical Significance: Stricter screening guidelines significantly improve maternal and infant health outcomes, but they present a massive financial burden on the national health system, requiring careful evaluation of cost-effectiveness.
Key Points for Patients: Changes in diagnostic guidelines mean more pregnant women are now diagnosed and treated for gestational diabetes. While this requires more medical visits and care, it is designed to keep both mother and baby safe from birth complications.
High but Stable Rates of Gestational Diabetes in Xiamen, China
Authors: Bing Yan, Yaxin Yu, Mingzhu Lin, Zhibin Li, Liying Wang, Peiying Huang, Haiqu Song, Xiulin Shi, Shuyu Yang, Xiaoying Li, Xuejun Li
Research Objective: To determine the overall rate, trend, and maternal risk factors for gestational diabetes among pregnant women in Xiamen, China.
Methods: A large population registry study tracked 78,572 pregnant women between 2011 and 2018 to analyze gestational diabetes trends and risk factors.
Main Findings: A total of 17.6% of the women were diagnosed with gestational diabetes, with the rate remaining fairly stable over the years. Key risk factors for developing the condition included older age (women over 40 had a much higher risk), obesity (2.5 times higher risk), family history of diabetes, high blood pressure, and excessive weight gain in early pregnancy.
Clinical Significance: Gestational diabetes affects a significant portion of pregnancies in this region. Managing body weight before conceiving and monitoring blood pressure and weight gain early in pregnancy are essential preventive steps.
Key Points for Patients: Planning for a healthy pregnancy includes aiming for a stable weight before conceiving, eating balanced meals, and avoiding rapid weight gain in the first few months of pregnancy to reduce your risk of gestational diabetes.
Validating a Portable Point-of-Care Device for Diabetic Nerve Damage
Authors: Yuka Shibata, Tatsuhito Himeno, Taeko Kamiya, Hiroya Tani, Takayuki Nakayama, Chika Kojima, Yukako Sugiura-Roth, Ena Naito, Masaki Kondo, Shin Tsunekawa, Yoshiro Kato, Jiro Nakamura, Hideki Kamiya
Research Objective: To evaluate if a user-friendly, portable hand-held device (NC-stat/DPNCheck™) is as reliable and accurate as large, standard laboratory equipment for diagnosing diabetic nerve damage (polyneuropathy).
Methods: Fifty-seven diabetes patients underwent nerve conduction tests using both the portable device and a standard electromyography system (EMGS), with measurements compared for consistency and repeatability.
Main Findings: Results from the portable device showed a strong correlation with the standard medical laboratory test. It also showed excellent reproducibility between different tests and when used by different health professionals.
Clinical Significance: This pocket-sized device can be easily used in small clinics without requiring expensive equipment or specialized laboratory technicians, potentially making screening for nerve damage much more accessible.
Key Points for Patients: Nerve damage is a common complication of diabetes that benefits from early detection. Portable testing devices make it easier and faster for your doctor to check your nerve health during regular office visits.
How the SGLT-2 Inhibitor Ipragliflozin Affects Weight Loss and Appetite Hormones
Authors: Hiroshi Miura, Kazuhiko Sakaguchi, Yuko Okada, Tomoko Yamada, Natsu Otowa-Suematsu, Anna So, Hisako Komada, Yushi Hirota, Takeshi Ohara, Yasuo Kuroki, Kenta Hara, Tomokazu Matsuda, Minoru Kishi, Akihiko Takeda, Kazuki Yokota, Yoshikazu Tamori, Wataru Ogawa
Research Objective: To investigate why patients taking SGLT-2 inhibitors sometimes lose less weight than expected, by exploring how the medication affects appetite-regulating hormones and hunger levels.
Methods: A 16-week clinical study monitored 96 patients with type 2 diabetes taking ipragliflozin, tracking changes in blood sugar, body weight, appetite scores, and levels of appetite-related hormones like leptin and ghrelin.
Main Findings: Patients successfully lowered their HbA1c levels and lost weight (an average loss of 2.6 kg). However, their levels of leptin (the "fullness" hormone) dropped significantly, and patients reported feeling noticeably hungrier after 2 and 8 weeks of treatment.
Clinical Significance: While ipragliflozin is highly effective for blood sugar control and weight loss, the natural hormonal response to calorie loss through urine is an increase in appetite, which can lead to increased food intake and limit weight loss.
Key Points for Patients: If you are taking an SGLT-2 inhibitor like ipragliflozin, you might find yourself feeling hungrier. Being aware of this change can help you plan satisfying, high-fiber, healthy meals to manage hunger and maximize your weight loss progress.
The Complex Relationship Between BMI and Diabetes Complications
Authors: Yongze Zhang, Yangyang Guo, Ximei Shen, Fengying Zhao, Sunjie Yan
Research Objective: To understand how different Body Mass Index (BMI) levels relate to the risk of vascular and nerve complications in patients with type 2 diabetes.
Methods: A retrospective study evaluated 3,224 type 2 diabetes patients, categorizing them into different BMI groups to analyze the risk of complications like nerve damage, kidney disease, and arterial plaque.
Main Findings: A U-shaped relationship was found for nerve damage (neuropathy) and leg artery disease (peripheral arterial disease)—meaning both very low and very high BMI levels carried a higher risk. Conversely, kidney disease and neck artery plaque risks rose steadily as BMI increased, while eye damage (retinopathy) showed no clear correlation with BMI.
Clinical Significance: This demonstrates that a very low BMI is not universally beneficial for all diabetes complications. Clinicians must realize that underweight and obese patients require different surveillance strategies for complications.
Key Points for Patients: Managing your weight is essential, but "lighter is not always better." Maintaining a healthy, stable weight in the normal range is the best way to protect your nerves, blood vessels, and kidneys.
Helicobacter pylori Infection Linked to Increased Risk of Diabetes
Authors: Masayuki Kato, Akiko Toda, Ritsuko Yamamoto-Honda, Yasuji Arase, Hirohito Sone
Research Objective: To determine if having a Helicobacter pylori (a common stomach bacteria) infection is associated with an increased risk of developing diabetes, and if treating the infection lowers that risk.
Methods: Researchers analyzed health data from 21,634 individuals undergoing health checkups, dividing them into groups based on whether they never had, currently have, or successfully cured (past) an H. pylori infection.
Main Findings: People with a current, active H. pylori infection had a 36% higher risk of diabetes compared to those who never had the infection. Crucially, those who had successfully treated and eradicated the bacteria in the past showed no increased risk of diabetes.
Clinical Significance: Chronic stomach inflammation from H. pylori may play a role in metabolic health, and testing for and treating this common infection might help reduce diabetes risk.
Key Points for Patients: H. pylori is a common bacterial infection in the stomach that can cause ulcers. If you test positive for this bacteria, completing the treatment to clear it from your system might also help support your long-term metabolic health.
Mobile Phone Application Enhances Blood Sugar Target Success in Type 2 Diabetes
Authors: Yuan Yu, Qun Yan, Huizhi Li, Hongmei Li, Lin Wang, Hua Wang, Yiyun Zhang, Lei Xu, Zhaosheng Tang, Xinfeng Yan, Yinghua Chen, Huili He, Jie Chen, Bo Feng
Research Objective: To evaluate how a specialized mobile phone app ("Diabetes-Carer"), with or without traditional finger-prick blood sugar monitoring, affects blood sugar control in diabetes patients.
Methods: A 24-week clinical trial randomized 185 patients into four groups: no app/no self-monitoring, self-monitoring only, app only, or both app and self-monitoring.
Main Findings: Over 60% of patients who used the mobile app (either alone or combined with finger-prick monitoring) achieved a target HbA1c of under 7.0%, compared to only 25.5% of those with no app. Interestingly, statistical analysis showed the mobile app was the primary driver of blood sugar improvement, while finger-prick self-monitoring alone had no significant independent effect on HbA1c reduction.
Clinical Significance: Utilizing digital mobile apps that provide structured self-management support can be highly effective in helping patients reach their clinical blood sugar targets, offering a modern alternative to traditional paper tracking.
Key Points for Patients: Managing diabetes isn't just about testing your blood sugar—it's about understanding and acting on the numbers. Using a diabetes self-management mobile app can keep you engaged, organized, and much more likely to hit your health targets.
